Segall Bryant & Hamill’s Meridian Bioscience Inc VIVO Stock Holding History

Segall Bryant & Hamill’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-164,672	Closed	-$2.9M	–	872
2019 Q1	$2.9M	Sell	164,672 -84,905	-34%	-$1.41M	0.05%	350
2018 Q4	$4.33M	Sell	249,577 -27,870	-10%	-$475K	0.07%	283
2018 Q3	$4.13M	Buy	277,447 +65,561	+31%	+$1.02M	0.06%	320
2018 Q2	$3.37M	Buy	+211,886	New	+$3.16M	0.05%	354

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Segall Bryant & Hamill's VIVO Position: Q2 2019 in Review

Segall Bryant & Hamill sold out of Meridian Bioscience Inc (VIVO) in Q2 2019, closing a stake of 164,672 shares — an estimated $2.9M sold.

Segall Bryant & Hamill first reported a position in VIVO in Q2 2018 and held it in 4 quarters. The position peaked at $4.33M in Q4 2018. 173 funds tracked by Wall St. Rank hold VIVO as of Q2 2019.

Segall Bryant & Hamill reported no remaining Meridian Bioscience Inc position as of Q2 2019 after selling out during the quarter.
Segall Bryant & Hamill sold 164,672 Meridian Bioscience Inc shares in Q2 2019, an estimated $2.9M.
Segall Bryant & Hamill first reported a position in Meridian Bioscience Inc in Q2 2018 and held it in 4 quarters.
Segall Bryant & Hamill's Meridian Bioscience Inc position peaked at $4.33M in Q4 2018.
173 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2019.

Based on Segall Bryant & Hamill's 13F filing for Q2 2019, filed 14 Aug 2019.